Xeris Biopharma Holdings, Inc. XERS EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Xeris Biopharma Holdings, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s EBITDA margin?
- Xeris Biopharma Holdings, Inc. (XERS) reported EBITDA margin of 11.8% in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s EBITDA margin changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s EBITDA margin increased by 214.7% year-over-year, from -10.3% to 11.8%.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s EBITDA margin?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s EBITDA margin has grown at a -55.5% compound annual growth rate (CAGR), from -229.5% to 9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.